CN105497783A - Application of traditional Chinese medicine preparation to preparing drug for treating qi stagnation and blood stasis type chloasma - Google Patents
Application of traditional Chinese medicine preparation to preparing drug for treating qi stagnation and blood stasis type chloasma Download PDFInfo
- Publication number
- CN105497783A CN105497783A CN201510959589.2A CN201510959589A CN105497783A CN 105497783 A CN105497783 A CN 105497783A CN 201510959589 A CN201510959589 A CN 201510959589A CN 105497783 A CN105497783 A CN 105497783A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine preparation
- fructus citri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention belongs to the field of traditional Chinese medicine and relates to application of a traditional Chinese medicine preparation to preparing drug for treating qi stagnation and blood stasis type chloasma. The traditional Chinese medicine preparation is prepared from Chinese mugwort leaves, rhizoma scirpi, roots and rhizomes of bloodred iris, radix curcumae, radix salvia, allium macrostemon, citron, citrus chirocarpus, stems of noble dendrobium, mulberry fruits, radix angelica sinensis, donkey-hide gelatin and licorice roots. The traditional Chinese medicine preparation has the functions of activating blood and removing blood stasis, soothing the liver and regulating qi and regulating qi activity, the curative effect is exact when the traditional Chinese medicine preparation is used for treating the qi stagnation and blood stasis type chloasma, and the traditional Chinese medicine preparation is safe and reliable and can effectively treat the qi stagnation and blood stasis type chloasma.
Description
Technical field
The invention belongs to the field of Chinese medicines, relate to the purposes of a kind of Chinese medicine preparation in preparation treatment qi stagnation and blood stasis type chloasma medicine.
Background technology
Along with social development, levels of substance improves constantly, the pursuit of people to U.S. is also strengthened gradually, especially women asks kindness to know obviously enhancing, and chloasma is as one of current damage capacitive disease, although skin lesion can not bring the discomfort such as patient pain, pruritus, it has a strong impact on instrument, often bring certain social pressure and mental pressure to patient, this is the problem that Medical circle and beauty treatment circle all pay special attention to.
Chloasma be a kind of with face local there is the calm dyskinetic dermatosis for cardinal symptom of filbert or brown pigment.Be mainly in the places such as forehead, two cheekbones, buccal, nose and mouth week, skin lesion is filbert to dark brown pigmentation spots, often symmetrical, without desquamation, clear border, smooth surface, local is without pain and pruritus, and after Exposure to Sunlight, pigment is deepened, and is generally mainly in female middle-aged and gravidic women.The traditional Chinese medical science thinks that primary disease is how in close relations with liver,spleen,kidney, and QI-blood failing to nourish upward is main pathogenesis in face.Differentiation of symptoms and signs for classification of syndrome is as follows: 1. liver-kidney yin deficiency: face is symmetrically formed brown patch, soreness of the waist and knees, sternal rib pain, dysphoria with feverish sensation in the chest palms and soles, sleeps not good enough; Women often has menoxenia or other chronic diseases; Thin white fur of tongue, stringy and thready pulse or heavy thin.The hepatic and renal YIN deficiency, qi-blood disharmony; 2. caused by hepatic stagnation qi stagnation: face is symmetrically formed yellowish-brown patch, fullness and distention in the chest and hypochondrium, emotion is irritable, and dreaminess is had a sleepless night; Stringy and rolling pulse or thin string; Stagnation of QI due to depression of the liver, qi-blood disharmony; 3. insufficiency of the spleen type of latent damp: speckle color ash is brown, shape such as dust adheres to, and with fatigue and weak, indigestion and loss of appetite sleepy, menstruation color is light, and leucorrhea amount is many, and pale tongue is fat, while there is indentation, tongue is greasy in vain, soft pulse or thin; Deficiency of spleen-QI is stagnant, wet stasis of blood spotting; 4, qi stagnation and blood stasis type: speckle color ash is brown or dark brown, mostly have chronic hepatitis medical history, or menstruation color secretly has clot, or a dysmenorrhea, dimly red tongue or have ecchymosis, tire is thin, hesitant pulse.
Current western medical treatment chloasma mainly adopts the combination of inner and outside, first will dispel the cause of disease, and strictly sun-proof.The medicine of western medicine chloasma is generally outer to be coated with, but outer painting is taken effect slowly, and can not reach the effect of radical cure, and the medicine for the treatment of by Chinese herbs chloasma is a lot, but the Chinese medicine for the treatment of qi stagnation and blood stasis type chloasma is targetedly little, and the compatibility of medicine is unreasonable also easily causes side effect.The patent of disclosed treatment qi stagnation and blood stasis type chloasma has a lot at present, such as: Chinese invention patent application numbers 201510118295.7,201510118295.7, wherein a kind ofly disclosed in Chinese invention patent application 201510118295.7 treat medicine of qi stagnation and blood stasis type chloasma and preparation method thereof, but it is clinical shows that onset is slow, the problems such as treatment cycle is longer.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of Chinese medicine preparation, it is made to give full play to the opsonic action of Chinese medicine, there is significant therapeutic effect to treatment qi stagnation and blood stasis type chloasma medicine, and be made into and facilitate easy-to-use finished product preparation, the rhythm of the modern life can be adapted to.
For realizing object of the present invention, technical solution of the present invention is as follows:
Chinese prescription of the present invention is expressed as with medical material weight proportion:
Folium Artemisiae Argyi 17-23 part, rhizoma scirpi 20-27 part, Radix et Rhizoma Iridis Sanguineae 15-20 part, Radix Curcumae 14-20 part, Radix Salviae Miltiorrhizae 13-18 part, Bulbus Allii Macrostemonis 11-17 part, Fructus Citri 7-13 part, Fructus Citri Sarcodactylis 8-13 part, Herba Dendrobii 9-16 part, Fructus Mori 10-15 part, Radix Angelicae Sinensis 7-15 part, Colla Corii Asini 6-11 part, Radix Glycyrrhizae 6-13 part.
In this ratio range, the most significant proportionings of preferred 3 curative effects:
Proportioning 1: Folium Artemisiae Argyi 17 parts, rhizoma scirpi 20 parts, Radix et Rhizoma Iridis Sanguineae 15 parts, Radix Curcumae 14 parts, Radix Salviae Miltiorrhizae 13 parts, Bulbus Allii Macrostemonis 11 parts, Fructus Citri 7 parts, Fructus Citri Sarcodactylis 8 parts, Herba Dendrobii 9 parts, Fructus Mori 10 parts, Radix Angelicae Sinensis 7 parts, 6 parts, Colla Corii Asini, 6 parts, Radix Glycyrrhizae.
Proportioning 2: Folium Artemisiae Argyi 23 parts, rhizoma scirpi 27 parts, Radix et Rhizoma Iridis Sanguineae 20 parts, Radix Curcumae 20 parts, Radix Salviae Miltiorrhizae 18 parts, Bulbus Allii Macrostemonis 17 parts, Fructus Citri 13 parts, Fructus Citri Sarcodactylis 13 parts, Herba Dendrobii 16 parts, Fructus Mori 15 parts, Radix Angelicae Sinensis 15 parts, 11 parts, Colla Corii Asini, 13 parts, Radix Glycyrrhizae.
Proportioning 3: Folium Artemisiae Argyi 21 parts, rhizoma scirpi 24 parts, Radix et Rhizoma Iridis Sanguineae 18 parts, Radix Curcumae 17 parts, Radix Salviae Miltiorrhizae 15 parts, Bulbus Allii Macrostemonis 13 parts, Fructus Citri 10 parts, Fructus Citri Sarcodactylis 11 parts, Herba Dendrobii 13 parts, Fructus Mori 12 parts, Radix Angelicae Sinensis 12 parts, 8 parts, Colla Corii Asini, 9 parts, Radix Glycyrrhizae.
The process above-mentioned prescription being made finished product Chinese medicine preparation is following steps:
Step (1), take each taste Chinese crude drug by Chinese prescription of the present invention;
Step (2), by Folium Artemisiae Argyi, rhizoma scirpi, Radix et Rhizoma Iridis Sanguineae, Radix Curcumae, Radix Salviae Miltiorrhizae, Bulbus Allii Macrostemonis, pulverize respectively, the concentration adding coarse powder gross weight 7-11 times weight after mixing is 65-75% ethanol, soaks 6-12 hour, reflux, extract, 2-3 time, each 2-5 hour, filter and retain filtering residue, merging filtrate, distilling under reduced pressure removing ethanol, and to be concentrated into 55-60 DEG C of relative density be the concentrated solution of 1.20-1.25, for subsequent use;
Step (3), Fructus Citri, Fructus Citri Sarcodactylis, Herba Dendrobii, Fructus Mori, Radix Angelicae Sinensis, Radix Glycyrrhizae to be pulverized respectively, the purified water of medical material gross weight 6-9 times weight will be added after filtering residue mixing described in step (2), backflow decocts 2-3 time, each 1-3 hour, filters, merging filtrate, being concentrated into 55-60 DEG C of relative density is the concentrated solution of 1.20-1.25, the concentrated solution obtained with step (2) merges, and mix homogeneously is for subsequent use;
Step (4), Caulis Bambusae In Taenia removing impurity, pulverizes, crosses 100-200 mesh sieve, obtain Caulis Bambusae In Taenia fine powder, for subsequent use;
Step (5), with boiled water, Colla Corii Asini is dissolved after, the Caulis Bambusae In Taenia fine powder obtained with the concentrated solution described in step (3) and step (4) is mixed homogeneously, and being evaporated to 55-60 DEG C of relative density is the thick paste of 1.30-1.35, is Chinese medical concrete;
Step (6), add suitable adjuvant, utilize modern general Chinese medicine preparation technology, step (5) gained Chinese medical concrete is made the Chinese medicine finished product preparation of clinical needs, as capsule, pill, granule, tablet or powder etc.
Source, the nature and flavor of Chinese prescription of the present invention Chinese crude drug used, return through and effect:
Folium Artemisiae Argyi: this product is the dried leaves of feverfew Chinese mugwort.Acrid in the mouth, hardship, warm in nature; Return liver,spleen,kidney warp; Dispersing cold for relieving pain, warming the meridian for stopping bleeding.
Rhizoma scirpi: be the dry tuber of Sparganiaceae plant rhizoma scirpi; Acrid in the mouth, hardship, property is put down; Return liver, spleen channel; Blood stasis dispelling stimulates the menstrual flow; Removing blood stasis eliminating mass; Circulation of qi promoting removing food stagnancy.
Radix et Rhizoma Iridis Sanguineae: Valerianaceae valerian rock limit is fragrant, with root or all herbal medicine; Acrid in the mouth, sweet, warm in nature; Return liver, the heart, lung meridian; Promoting blood flow to regulate menstruation, eliminating stasis to stop pain, spleen invigorating removing food stagnancy.
Radix Curcumae: this product is the dried root of zingiberaceous plant RADIX CURCUMAE, Rhizoma Curcumae Longae, Guangxi zedoary or Rhizoma Curcumae; Acrid in the mouth, hardship, cold in nature; Return liver, the heart, lung meridian; Regulating qi to disperse stagnation, heart fire-clearing upset-relieving, promoting the function of the gallbladder to alleviate jaundice.
Radix Salviae Miltiorrhizae: this product is the dry root and rhizome of labiate Radix Salviae Miltiorrhizae; Bitter in the mouth, cold nature; GUIXIN, Liver Channel; Stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, clear away heart-fire relieving restlessness.
Bulbus Allii Macrostemonis: this product is the dry bulb of liliaceous plant Allium macrostemon or Chinese onion; Pungent, bitter, temperature; Return lung, stomach, large intestine channel; Activating YANG and eliminating stagnation, circulation of qi promoting intestinal stasis relieving.
Fructus Citri: this product is the dry mature fruit of rutaceae citron or fragrant circle (the fragrant circle in southwest); Acrid in the mouth, hardship, acid, warm in nature; Return liver, spleen, lung meridian; Liver-smoothing, qi-regulating, alleviating distention in middle-JIAO, reduces phlegm.
Fructus Citri Sarcodactylis: be the fruit of rutaceae Fructus Citri Sarcodactylis; Acrid in the mouth picric acid, warm in nature; Enter liver, stomach warp; Regulate the flow of vital energy, reduce phlegm.
Herba Dendrobii: this product is the fresh or dry stem of orchid dendrobium loddigesii Rolfe, Herba Dendrobii oculati, HERBA DENDROBII, Herba Dendrobii or Dendrobium nobile; Sweet in the mouth, cold nature; Return stomach, kidney channel; Reinforcing stomach reg fluid, nourishing YIN and clearing away heat.
Fructus Mori: be the fruit ear of moraceae plants Mulberry; Sweet in the mouth, acid, cold in nature; Return liver, kidney channel; Nourishing YIN and benefiting blood; Promote the production of body fluid; Intestine moistening.
Radix Angelicae Sinensis: this product is the dry root of umbelliferae angelica; Sweet in the mouth is pungent, warm in nature; Enter the heart, liver, spleen channel; Benefiting blood and regulating blood circulation, menstruction regulating and pain relieving, moisturizes laxation.
Colla Corii Asini: this product is that the skin of equine species donkey is through decocting, concentrating the solid gum made; Sweet in the mouth, property is put down; Return lung, liver, kidney channel; To enrich blood YIN nourishing, moisturize, hemostasis.
Radix Glycyrrhizae: this product is the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L.; Sweet in the mouth, property is put down; GUIXIN, lung, spleen, stomach warp; Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
The compatibility analysis of Chinese prescription of the present invention:
Chinese prescription of the present invention to the dialectical cognition of qi stagnation and blood stasis type chloasma, follows the compatibility theory of Chinese medicine according to the traditional Chinese medical science, facilitating the easy-to-use and preparation of stable curative effect, enhancing the use amount of medical material to make.This prescription is with Folium Artemisiae Argyi, rhizoma scirpi for monarch drug, soothing the liver circulation of qi promoting, nourishing blood for regulating menstruation; With Radix et Rhizoma Iridis Sanguineae, Radix Curcumae, Radix Salviae Miltiorrhizae, Bulbus Allii Macrostemonis for ministerial drug, circulation of qi promoting regulate the flow of vital energy, dispersing the stagnated live-QI to relieve the stagnation of QI, promoting blood circulation to restore menstrual flow; With Fructus Citri, Fructus Citri Sarcodactylis, Herba Dendrobii, Fructus Mori, when being classified as adjuvant drug, invigorating the spleen and benefiting QI, with strong source of generating QI and blood, to reach the merit of the capable then blood of gas, to reach QI and blood sum; With Colla Corii Asini and Radix Glycyrrhizae for making medicine, the coordinating the actions of various ingredients in a prescription property of medicine, all medicines coordinate, and complement each other, synergism, by resolving blood stasis and dredging collateral, improve circulation, thus adjustment endocrine, eliminate alluvial in body, make function of human body return to good physiological status.
Compared with prior art, Chinese medicine of the present invention has good effect, treating both the principal and secondary aspects of a disease, stresses treatment advantages such as nursing one's health, toxic and side effects is little, and, Chinese medicine of the present invention can also make universality strong, facilitate easy-to-use finished product preparation, overcome Chinese medicine not portablely to take, the shortcoming such as individual variation is large, its preparation technology is simple and easy to do, preparation efficacy stability, be easy to apply.
Detailed description of the invention
Below will the present invention is described further by specific embodiment, it will be understood by those skilled in the art that the present invention also can make other similar changes and obtains similar result and do not depart from content of the present invention and scope except following examples.
Embodiment one
The embodiment of the present invention 1 Chinese medicine preparation comprises the Chinese crude drug of following weight portion:
Folium Artemisiae Argyi 17 parts, rhizoma scirpi 20 parts, Radix et Rhizoma Iridis Sanguineae 15 parts, Radix Curcumae 14 parts, Radix Salviae Miltiorrhizae 13 parts, Bulbus Allii Macrostemonis 11 parts, Fructus Citri 7 parts, Fructus Citri Sarcodactylis 8 parts, Herba Dendrobii 9 parts, Fructus Mori 10 parts, Radix Angelicae Sinensis 7 parts, 6 parts, Colla Corii Asini, 6 parts, Radix Glycyrrhizae.
Preparation method is as follows:
Step (1), take each taste Chinese crude drug by Chinese prescription of the present invention;
Step (2), by Folium Artemisiae Argyi, rhizoma scirpi, Radix et Rhizoma Iridis Sanguineae, Radix Curcumae, Radix Salviae Miltiorrhizae, Bulbus Allii Macrostemonis, pulverize respectively, the concentration adding coarse powder gross weight 7-11 times weight after mixing is 75% ethanol, soaks 12 hours, reflux, extract, 3 times, each 5 hours, filter and retain filtering residue, merging filtrate, distilling under reduced pressure removing ethanol, and to be concentrated into 60 DEG C of relative densities be the concentrated solution of 1.25, for subsequent use;
Step (3), Fructus Citri, Fructus Citri Sarcodactylis, Herba Dendrobii, Fructus Mori, Radix Angelicae Sinensis, Radix Glycyrrhizae to be pulverized respectively, the purified water of medical material gross weight 9 times of weight will be added after filtering residue mixing described in step (2), backflow decoction 3 times, each 3 hours, filter, merging filtrate, being concentrated into 60 DEG C of relative densities is the concentrated solution of 1.25, the concentrated solution obtained with step (2) merges, and mix homogeneously is for subsequent use;
Step (4), Caulis Bambusae In Taenia removing impurity, pulverizes, crosses 200 mesh sieves, obtain Caulis Bambusae In Taenia fine powder, for subsequent use;
Step (5), with boiled water, Colla Corii Asini is dissolved after, the Caulis Bambusae In Taenia fine powder obtained with the concentrated solution described in step (3) and step (4) is mixed homogeneously, and being evaporated to 60 DEG C of relative densities is the thick paste of 1.35, is Chinese medical concrete;
Step (6), add suitable adjuvant, utilize modern general Chinese medicine preparation technology, step (5) gained Chinese medical concrete is made capsule.
Embodiment two
The embodiment of the present invention 2 Chinese medicine preparation comprises the Chinese crude drug of following weight portion:
Folium Artemisiae Argyi 23 parts, rhizoma scirpi 27 parts, Radix et Rhizoma Iridis Sanguineae 20 parts, Radix Curcumae 20 parts, Radix Salviae Miltiorrhizae 18 parts, Bulbus Allii Macrostemonis 17 parts, Fructus Citri 13 parts, Fructus Citri Sarcodactylis 13 parts, Herba Dendrobii 16 parts, Fructus Mori 15 parts, Radix Angelicae Sinensis 15 parts, 11 parts, Colla Corii Asini, 13 parts, Radix Glycyrrhizae.
Preparation method is as embodiment one.
Embodiment three
The embodiment of the present invention 3 Chinese medicine preparation comprises the Chinese crude drug of following weight portion:
Folium Artemisiae Argyi 21 parts, rhizoma scirpi 24 parts, Radix et Rhizoma Iridis Sanguineae 18 parts, Radix Curcumae 17 parts, Radix Salviae Miltiorrhizae 15 parts, Bulbus Allii Macrostemonis 13 parts, Fructus Citri 10 parts, Fructus Citri Sarcodactylis 11 parts, Herba Dendrobii 13 parts, Fructus Mori 12 parts, Radix Angelicae Sinensis 12 parts, 8 parts, Colla Corii Asini, 9 parts, Radix Glycyrrhizae.
Preparation method is as embodiment one.
Embodiment four
The embodiment of the present invention 4 Chinese medicine preparation comprises the Chinese crude drug of following weight portion:
Folium Artemisiae Argyi 22 parts, rhizoma scirpi 25 parts, Radix et Rhizoma Iridis Sanguineae 19 parts, Radix Curcumae 18 parts, Radix Salviae Miltiorrhizae 17 parts, Bulbus Allii Macrostemonis 15 parts, Fructus Citri 12 parts, Fructus Citri Sarcodactylis 12 parts, Herba Dendrobii 15 parts, Fructus Mori 14 parts, Radix Angelicae Sinensis 14 parts, 10 parts, Colla Corii Asini, 9 parts, Radix Glycyrrhizae.
Preparation method is as embodiment one.
Experimental example one
Chinese medicine preparation of the present invention is to the improvement result of rat blood stasis models
Get healthy SD rat, body weight 180-200g, 60, male and female half and half, be divided into 6 groups at random: Normal group, model group, PAIDU YANGYAN JIAONANG group (Yunnan Panlongyunhai Pharmaceutical Co., Ltd., traditional Chinese medicines accurate word Z53020685) and the basic, normal, high dosage group of Chinese medicine preparation of the present invention, often organize 10.Gastric infusion, successive administration 14 days, Normal group and model group are to 0.5%CMC, and all the other give corresponding medicine, and dosage regimen is as follows:
PAIDU YANGYAN JIAONANG group: gavage gives the PAIDU YANGYAN JIAONANG of 1g/kg;
Chinese medicine preparation low dose group: gavage gives Chinese medicine preparation 0.5g/kg prepared by the embodiment of the present invention 1;
Dosage group in Chinese medicine preparation: gavage gives Chinese medicine preparation 1g/kg prepared by the embodiment of the present invention 1;
Chinese medicine preparation high dose group: gavage gives Chinese medicine preparation 2g/kg prepared by the embodiment of the present invention 1.
Successive administration is after the 13rd day, and except Normal group, all the other treated animals press the injected sc adrenalin hydrochloride of 1g/kg, 2 times/day, interval 4h, and after first time injection, animal is put into 15min in 4 DEG C of frozen water by 2h.Administration is got 4-5ml blood anticoagulant heparin on the 15th day and is measured blood rheology parameter.
Table 1 Chinese medicine composition of the present invention is on the impact of rat blood stasis models lectin from hemolymph
Note: compare with normal control,
#p < 0.05,
##p < 0.01; Compare with model group,
*p < 0.05,
*p < 0.01; Compare with positive controls,
?p < 0.05.
Result shows, and model group compares with normal control, and each hemorheology index of rat all has and significantly increases (P<0.01).Compare with model group, Chinese medicine composition of the present invention each dosage group basic, normal, high all significantly reduces the level (P<0.05 or P<0.01) of each hemorheology index of rat, wherein, the effect of middle low dose group is suitable with PAIDU YANGYAN JIAONANG group, and the whole blood viscosity of high dose group and plasma viscosity have significant difference (P<0.05) compared with PAIDU YANGYAN JIAONANG group, test illustrates that the therapeutic effect of Chinese medicine composition of the present invention to blood stasis is remarkable.
Experimental example two
The clinical data of medicine composite for curing chloasma of the present invention
One, case-data: choose the 206 routine women's qi stagnation and blood stasis type patient with chloasma meeting Screening Diagnosis standard of hospital's Dermatology and outpatient service as object of study, meet with symptom: yellowish-brown patch appears in face, soreness of the waist and knees, or being irritable and getting angry easily, distending pain in the chest and hypochondrium.Dark tongue quality, white and thin fur, deep-thready pulse.Be divided into treatment group and matched group at random.
Treatment group 103 example, age 23-48 year, the mean age (28.3 ± 4.1) year; The course of disease 8 months-9 years, average course of disease (3.7 ± 2.7) year.Matched group 103 example, year 21-46 year, the mean age (29.1 ± 4.4) year; The course of disease 10 months-9 years, average course of disease (3.5 ± 2.8) year.Two groups of patient's physical data no significant differences, P>0.05, has comparability.
Two, diagnostic criteria:
1, diagnosis basis:
1) facial skin lesion is black speck, puts down in skin, and color is as dust and dirt, and light brown or light black, without pain of itching.
2) facial areas such as volume, eyebrow, cheek, bridge of the nose, lip are often occurred in.
3) be more common in woman, onset has chronic process.
4) tissue pathology checking shows hyperpigmentation in epidermis, also has more pigment in corium addicted to melanocyte.Minority lymphocytic infiltration can be had at blood vessel and perifollicolar.
2, case selection:
1) age is between 20-55 year;
2) without Diseases such as serious endocrine;
3) to medicine without allergies person;
4) without gestation or women breast-feeding their children.
3, to reject and the standard that comes off
1) experimenter's compliance is poor, does not treat by doctor's advice;
2) data is incomplete, affects the treatment or safety judgement person;
3) because of untoward reaction discontinue medication person;
4) there is anaphylaxis, serious adverse events and special physiological change palpus stopped treatment person in therapeutic process;
5) can not the tolerate treatment person of dropping by the wayside in research process;
6) treatments period, takes other treatment medicine, likely the Study of Interference result person;
7) other clinical trial persons are participated in.
Three, therapeutic scheme:
Treatment group: made Chinese medicine capsules of the present invention (every containing crude drug amount 0.6g) in the embodiment of the present invention 1, each 2, every day 3 times, oral.
Matched group: each 4 of PAIDU YANGYAN JIAONANG (Yunnan Panlongyunhai Pharmaceutical Co., Ltd., traditional Chinese medicines accurate word Z53020685), every day 3 times, oral.
Two groups was all a course for the treatment of with 4 weeks, judged curative effect after treating 1 course for the treatment of.Period in a medicine polyphagia fruit, vegetable, drink plain boiled water more, and fasting or few edible oil explode, pungent irritating food.
Four, criterion of therapeutical effect:
The chloasma criterion of therapeutical effect of revision in 2003 is organized with reference to Dermatology Professional Committee of CAIM (Chinese Association Of Integrative Medicine) pigment disease.
Cure: naked eyes disappear depending on mottle area and are greater than 90%, and color disappears substantially.
Effective: meat is greater than 60% with disappearing depending on mottle area, and color is obviously thin out.
Take a turn for the better: naked eyes disappear depending on mottle area, and to be greater than 30%. colors thin out.
Invalid: naked eyes disappear depending on mottle area and are less than 30%, color change is not obvious.
Total effective rate=(cure+effective+effectively)/total number of cases × 100%
Five, therapeutic effect:
The treatment total effective rate for the treatment of group is 96.12%, and matched group is 76.70%, visible, and the treatment total effective rate for the treatment of group is apparently higher than matched group, and two groups all do not occur serious untoward reaction.Concrete outcome, in table 2, shows to use Chinese medicine preparation of the present invention to treat qi stagnation and blood stasis type chloasma determined curative effect, safe and reliable, can be used as the effective ways for the treatment of chloasma.
The comparitive study of table 2 treatment group and matched group
Owing to describing the present invention by above preferred embodiment, in spirit of the present invention and/or scope, any for replacement/of the present invention or combination implement the present invention, be all apparent for a person skilled in the art, and be included among the present invention.
Claims (6)
1. the purposes of Chinese medicine preparation in preparation treatment qi stagnation and blood stasis type chloasma medicine, it is characterized in that, described Chinese medicine preparation comprises the raw materials of following weight portion:
Folium Artemisiae Argyi 17-23 part, rhizoma scirpi 20-27 part, Radix et Rhizoma Iridis Sanguineae 15-20 part, Radix Curcumae 14-20 part, Radix Salviae Miltiorrhizae 13-18 part, Bulbus Allii Macrostemonis 11-17 part, Fructus Citri 7-13 part, Fructus Citri Sarcodactylis 8-13 part, Herba Dendrobii 9-16 part, Fructus Mori 10-15 part, Radix Angelicae Sinensis 7-15 part, Colla Corii Asini 6-11 part, Radix Glycyrrhizae 6-13 part.
2. purposes according to claim 1, is characterized in that, described Chinese medicine preparation comprises the raw materials of following weight portion:
Folium Artemisiae Argyi 17 parts, rhizoma scirpi 20 parts, Radix et Rhizoma Iridis Sanguineae 15 parts, Radix Curcumae 14 parts, Radix Salviae Miltiorrhizae 13 parts, Bulbus Allii Macrostemonis 11 parts, Fructus Citri 7 parts, Fructus Citri Sarcodactylis 8 parts, Herba Dendrobii 9 parts, Fructus Mori 10 parts, Radix Angelicae Sinensis 7 parts, 6 parts, Colla Corii Asini, 6 parts, Radix Glycyrrhizae.
3. purposes according to claim 1, is characterized in that, described Chinese medicine preparation comprises the raw materials of following weight portion:
Folium Artemisiae Argyi 23 parts, rhizoma scirpi 27 parts, Radix et Rhizoma Iridis Sanguineae 20 parts, Radix Curcumae 20 parts, Radix Salviae Miltiorrhizae 18 parts, Bulbus Allii Macrostemonis 17 parts, Fructus Citri 13 parts, Fructus Citri Sarcodactylis 13 parts, Herba Dendrobii 16 parts, Fructus Mori 15 parts, Radix Angelicae Sinensis 15 parts, 11 parts, Colla Corii Asini, 13 parts, Radix Glycyrrhizae.
4. purposes according to claim 1, is characterized in that, described Chinese medicine preparation comprises the raw materials of following weight portion:
Folium Artemisiae Argyi 21 parts, rhizoma scirpi 24 parts, Radix et Rhizoma Iridis Sanguineae 18 parts, Radix Curcumae 17 parts, Radix Salviae Miltiorrhizae 15 parts, Bulbus Allii Macrostemonis 13 parts, Fructus Citri 10 parts, Fructus Citri Sarcodactylis 11 parts, Herba Dendrobii 13 parts, Fructus Mori 12 parts, Radix Angelicae Sinensis 12 parts, 8 parts, Colla Corii Asini, 9 parts, Radix Glycyrrhizae.
5. purposes according to claim 1, is characterized in that, described Chinese medicine preparation preparation technology is following steps:
Step (1), take each taste Chinese crude drug by Chinese prescription of the present invention;
Step (2), by Folium Artemisiae Argyi, rhizoma scirpi, Radix et Rhizoma Iridis Sanguineae, Radix Curcumae, Radix Salviae Miltiorrhizae, Bulbus Allii Macrostemonis, pulverize respectively, the concentration adding coarse powder gross weight 7-11 times weight after mixing is 65-75% ethanol, soaks 6-12 hour, reflux, extract, 2-3 time, each 2-5 hour, filter and retain filtering residue, merging filtrate, distilling under reduced pressure removing ethanol, and to be concentrated into 55-60 DEG C of relative density be the concentrated solution of 1.20-1.25, for subsequent use;
Step (3), Fructus Citri, Fructus Citri Sarcodactylis, Herba Dendrobii, Fructus Mori, Radix Angelicae Sinensis, Radix Glycyrrhizae to be pulverized respectively, the purified water of medical material gross weight 6-9 times weight will be added after filtering residue mixing described in step (2), backflow decocts 2-3 time, each 1-3 hour, filters, merging filtrate, being concentrated into 55-60 DEG C of relative density is the concentrated solution of 1.20-1.25, the concentrated solution obtained with step (2) merges, and mix homogeneously is for subsequent use;
Step (4), Caulis Bambusae In Taenia removing impurity, pulverizes, crosses 100-200 mesh sieve, obtain Caulis Bambusae In Taenia fine powder, for subsequent use;
Step (5), with boiled water, Colla Corii Asini is dissolved after, the Caulis Bambusae In Taenia fine powder obtained with the concentrated solution described in step (3) and step (4) is mixed homogeneously, and being evaporated to 55-60 DEG C of relative density is the thick paste of 1.30-1.35, is Chinese medical concrete;
Step (6), add suitable adjuvant, utilize modern general Chinese medicine preparation technology, step (5) gained Chinese medical concrete is made the Chinese medicine finished product preparation of clinical needs.
6. the purposes as described in as arbitrary in claim 1-5, it is characterized in that, described Chinese medicine preparation is made as capsule, pill, granule, tablet or powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510959589.2A CN105497783A (en) | 2015-12-21 | 2015-12-21 | Application of traditional Chinese medicine preparation to preparing drug for treating qi stagnation and blood stasis type chloasma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510959589.2A CN105497783A (en) | 2015-12-21 | 2015-12-21 | Application of traditional Chinese medicine preparation to preparing drug for treating qi stagnation and blood stasis type chloasma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105497783A true CN105497783A (en) | 2016-04-20 |
Family
ID=55706335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510959589.2A Withdrawn CN105497783A (en) | 2015-12-21 | 2015-12-21 | Application of traditional Chinese medicine preparation to preparing drug for treating qi stagnation and blood stasis type chloasma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105497783A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107970373A (en) * | 2017-12-20 | 2018-05-01 | 南宁多灵生物科技有限公司 | A kind of pharmaceutical composition for treating chloasma |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491672A (en) * | 2014-12-29 | 2015-04-08 | 广东聚智诚科技有限公司 | Traditional Chinese medicine preparation for treating chronic tracheitis and preparation method thereof |
| CN104491695A (en) * | 2014-12-05 | 2015-04-08 | 广东聚智诚科技有限公司 | Pharmaceutical composition for treating chloasma |
-
2015
- 2015-12-21 CN CN201510959589.2A patent/CN105497783A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491695A (en) * | 2014-12-05 | 2015-04-08 | 广东聚智诚科技有限公司 | Pharmaceutical composition for treating chloasma |
| CN104491672A (en) * | 2014-12-29 | 2015-04-08 | 广东聚智诚科技有限公司 | Traditional Chinese medicine preparation for treating chronic tracheitis and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王兆海: "中西医结合治疗黄褐斑", 《云南中医中药杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107970373A (en) * | 2017-12-20 | 2018-05-01 | 南宁多灵生物科技有限公司 | A kind of pharmaceutical composition for treating chloasma |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105147847A (en) | Drug composition for benefiting qi and nourishing blood | |
| CN104338062A (en) | Chinese medicinal preparation for treating stomachache and diarrhea | |
| CN104127699A (en) | Vitality-tonifying health-preserving preparation and preparation method thereof | |
| CN104491801A (en) | Traditional Chinese medicine preparation for treating acute or chronic gastritis and preparation method thereof | |
| CN102210820A (en) | Chinese medicinal composition for treating leukemia | |
| CN107715067B (en) | Pharmaceutical composition for conditioning blood stasis constitution and preparation method and application thereof | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN104510971A (en) | Chinese medicinal preparation for treatment of habitual abortion | |
| CN103127472A (en) | Traditional Chinese medicine compound for refractory insomnia | |
| CN104888131A (en) | Traditional Chinese medicine composition for treatment of insomnia | |
| CN105362776B (en) | A kind of Chinese medicine composition for treating hyperthyroidism, preparation method and applications | |
| CN101279034B (en) | Combined Chinese medicament for curing diabetic with combined internal and external therapies and preparation thereof | |
| CN105796845A (en) | Application of medicine composition in preparing medicine for treating female climacteric syndromes | |
| CN102133167A (en) | Freckle removing facial mask made of traditional Chinese medicine and preparation process thereof | |
| CN104984296A (en) | Pharmaceutical composition for treating female climacteric syndrome and preparation method thereof | |
| CN104225507A (en) | Chinese medicine for treating limb paralysis and pain caused by cerebral hemorrhage | |
| CN103550549A (en) | Traditional Chinese medicine (TCM) composition for treating deficiency of heart-yin | |
| CN103690780A (en) | Heart-invigorating and sedative pill and preparation method thereof | |
| CN105497783A (en) | Application of traditional Chinese medicine preparation to preparing drug for treating qi stagnation and blood stasis type chloasma | |
| CN105343675A (en) | Traditional Chinese medicine preparation for treating adiposis and preparation method thereof | |
| CN106581299B (en) | Traditional Chinese medicine composition for improving kidney qi deficiency of middle-aged and old people and application thereof | |
| CN105362630A (en) | Climacteric syndrome treatment pharmaceutical composition and preparation method thereof | |
| CN1149095C (en) | Chinese medicine for treating baby's congenital heart disease | |
| CN104056017A (en) | Traditional Chinese medicine composition for treating rheumatism and preparation method thereof | |
| CN103751418A (en) | Traditional Chinese medicine composition for treating restless leg syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160420 |
|
| WW01 | Invention patent application withdrawn after publication |